Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Open access

Published version of a preprint

Abstract

The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or a few subtypes. Herein, we report a comparative genetic analysis of 2,138 sarcomas representing 45 pathological entities. This cohort is prospectively analyzed using targeted sequencing to characterize subtype-specific somatic alterations in targetable pathways, rates of whole genome doubling, mutational signatures, and subtype-agnostic genomic clusters. The most common alterations are in cell cycle control and TP53 , receptor tyrosine kinases/PI3K/RAS, and epigenetic regulators. Subtype-specific associations include TERT amplification in intimal sarcoma and SWI/SNF alterations in uterine adenosarcoma. Tumor mutational burden, while low compared to other cancers, varies between and within subtypes. This resource will improve sarcoma models, motivate studies of subtype-specific alterations, and inform investigations of genetic factors and their correlations with treatment response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-30453-x

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Analysis of 2138 sarcoma samples reveals variation in patient characteristics among subtypes. This analysis includes 2138 bone and soft tissue sarcoma samples, each from distinct patients. Subtypes with ≥20 samples in the dataset are displayed. A Distribution of number of samples, survival from time of sequencing, sample type (primary or metastatic site), tumor site, sample purity, age, sex, and self-reported race in each subtype. Retro/IA, retroperitoneal or intrabdominal. NA, not applicable. In the age plot, box boundaries indicate 25th and 75th percentiles, interior lines medians, and whiskers 1.5 times the interquartile range. B Overall distribution of sample number for the entire cohort. C 1, 3, and 5-year survival from the time of sequencing. *, 5-year survival = 0. Vertical lines indicate 95% confidence intervals. DES desmoid tumor, ESS endometrial stromal sarcoma, INT intimal sarcoma, LGFMS low-grade fibromyxoid sarcoma, EMCHS extraskeletal myxoid chondrosarcoma, HGESS high-grade endometrial stromal sarcoma, LGESS low-grade endometrial stromal sarcoma, SEF sclerosing epithelioid fibrosarcoma, ASPS alveolar soft part sarcoma, DDCHS dedifferentiated chondrosarcoma, UAS uterine adenosarcoma, SCSRMS spindle cell/sclerosing rhabdomyosarcoma, CCS clear cell sarcoma, EHAE epithelioid hemangioendothelioma.
Fig. 1 Analysis of 2138 sarcoma samples reveals variation in patient characteristics among subtypes. This analysis includes 2138 bone and soft tissue sarcoma samples, each from distinct patients. Subtypes with ≥20 samples in the dataset are displayed. A Distribution of number of samples, survival from time of sequencing, sample type (primary or metastatic site), tumor site, sample purity, age, sex, and self-reported race in each subtype. Retro/IA, retroperitoneal or intrabdominal. NA, not applicable. In the age plot, box boundaries indicate 25th and 75th percentiles, interior lines medians, and whiskers 1.5 times the interquartile range. B Overall distribution of sample number for the entire cohort. C 1, 3, and 5-year survival from the time of sequencing. *, 5-year survival = 0. Vertical lines indicate 95% confidence intervals. DES desmoid tumor, ESS endometrial stromal sarcoma, INT intimal sarcoma, LGFMS low-grade fibromyxoid sarcoma, EMCHS extraskeletal myxoid chondrosarcoma, HGESS high-grade endometrial stromal sarcoma, LGESS low-grade endometrial stromal sarcoma, SEF sclerosing epithelioid fibrosarcoma, ASPS alveolar soft part sarcoma, DDCHS dedifferentiated chondrosarcoma, UAS uterine adenosarcoma, SCSRMS spindle cell/sclerosing rhabdomyosarcoma, CCS clear cell sarcoma, EHAE epithelioid hemangioendothelioma.CC BY · PubMed Central
Fig. 2 Mutation analysis by subtype. A Alteration type and frequency, fraction of genome altered (FGA) and tumor mutation burden (TMB) by subtype. Oncogenic fusions detected by MSK-IMPACT are classified as drivers. In the FGA and TMB plots, box boundaries indicate 25th and 75th percentiles, interior lines medians, and whiskers 1.5 times the interquartile range. VUS variant of unknown significance. B Significant mutations were identified in all subtypes with n ≥ 20 in our dataset using both MutSig and MuSiC analysis. Percentages indicate the percentage of samples with an oncogenic mutation in the corresponding gene. C FLT4 mutation type, frequency, and location in ANGS vs. other subtypes. D Cancer cell fraction (CCF) and number of mutations for driver mutations and VUS by subtype. Circles indicate medians and vertical lines interquartile ranges.
Fig. 2 Mutation analysis by subtype. A Alteration type and frequency, fraction of genome altered (FGA) and tumor mutation burden (TMB) by subtype. Oncogenic fusions detected by MSK-IMPACT are classified as drivers. In the FGA and TMB plots, box boundaries indicate 25th and 75th percentiles, interior lines medians, and whiskers 1.5 times the interquartile range. VUS variant of unknown significance. B Significant mutations were identified in all subtypes with n ≥ 20 in our dataset using both MutSig and MuSiC analysis. Percentages indicate the percentage of samples with an oncogenic mutation in the corresponding gene. C FLT4 mutation type, frequency, and location in ANGS vs. other subtypes. D Cancer cell fraction (CCF) and number of mutations for driver mutations and VUS by subtype. Circles indicate medians and vertical lines interquartile ranges.CC BY · PubMed Central
Fig. 3 Copy number changes by subtype. Copy number alteration (CNA) and whole-genome doubling events (WGD) compared across subtypes. A Individual sample CNA across the genome for each subtype. WGD, fraction genome altered (FGA), and purity are shown at right. B Aggregate arm-level (left) and gene-level events (right) grouped by subtype. *significant change based on Bonferroni corrected p-values. Significance was evaluated by random permutations testing. Oncogenic (bold) vs. non-oncogenic CNA classifications according to OncoKB. C Frequency of WGD by subtype (green) compared to other cancers with ≥200 samples available for comparison (gray)13. NSCLC, non-small cell lung cancer; ST, soft tissue. D, Overall survival based on WGD status within primary and metastatic samples. p.adj, adjusted p-value.
Fig. 3 Copy number changes by subtype. Copy number alteration (CNA) and whole-genome doubling events (WGD) compared across subtypes. A Individual sample CNA across the genome for each subtype. WGD, fraction genome altered (FGA), and purity are shown at right. B Aggregate arm-level (left) and gene-level events (right) grouped by subtype. *significant change based on Bonferroni corrected p-values. Significance was evaluated by random permutations testing. Oncogenic (bold) vs. non-oncogenic CNA classifications according to OncoKB. C Frequency of WGD by subtype (green) compared to other cancers with ≥200 samples available for comparison (gray)13. NSCLC, non-small cell lung cancer; ST, soft tissue. D, Overall survival based on WGD status within primary and metastatic samples. p.adj, adjusted p-value.CC BY · PubMed Central
Fig. 4 Integrated pathway analysis. A Oncogenic alterations within each of 12 pathways with relevance to cancer biology in each subtype. Numbers in each cell indicate percentage of samples harboring alterations. Stacked bar graphs indicate the distribution of the type of oncogenic alteration per gene or pathway (top) or subtype (right). CC, cell cycle; DDR, DNA damage repair; EPI, epigenetic. B PI3K pathway alterations in specific subtypes. The percentage of samples with an alteration in a specific gene in each subtype is indicated in each box. C Oncogenic TERT alterations in each of the 9 most altered subtypes. D Oncogenic epigenetic pathway alterations by subtype, grouped by complex and/or biochemical function of the encoded protein. Totals include all alterations in genes that belong to a parent category, not only those affecting specific complexes listed.
Fig. 4 Integrated pathway analysis. A Oncogenic alterations within each of 12 pathways with relevance to cancer biology in each subtype. Numbers in each cell indicate percentage of samples harboring alterations. Stacked bar graphs indicate the distribution of the type of oncogenic alteration per gene or pathway (top) or subtype (right). CC, cell cycle; DDR, DNA damage repair; EPI, epigenetic. B PI3K pathway alterations in specific subtypes. The percentage of samples with an alteration in a specific gene in each subtype is indicated in each box. C Oncogenic TERT alterations in each of the 9 most altered subtypes. D Oncogenic epigenetic pathway alterations by subtype, grouped by complex and/or biochemical function of the encoded protein. Totals include all alterations in genes that belong to a parent category, not only those affecting specific complexes listed.CC BY · PubMed Central
Fig. 5 Mutual exclusivity, co-occurrence, ATRX alterations, and unsupervised clustering based on genetic signatures. A Co-occurrence and mutual exclusivity of gene- (top) and pathway-level (bottom) alterations in each subtype with significant findings shown. Significance was evaluated by two-sided Fisher’s exact test. EPI, epigenetic; DDR, DNA damage repair. B Frequency and types of oncogenic ATRX alterations in each of the 14 most altered subtypes. C Unsupervised clustering of all samples based on oncogenic alteration patterns. D Subtype-specific cluster associations and entropy scores. For clarity, subtypes with n > 5 are displayed.
Fig. 5 Mutual exclusivity, co-occurrence, ATRX alterations, and unsupervised clustering based on genetic signatures. A Co-occurrence and mutual exclusivity of gene- (top) and pathway-level (bottom) alterations in each subtype with significant findings shown. Significance was evaluated by two-sided Fisher’s exact test. EPI, epigenetic; DDR, DNA damage repair. B Frequency and types of oncogenic ATRX alterations in each of the 14 most altered subtypes. C Unsupervised clustering of all samples based on oncogenic alteration patterns. D Subtype-specific cluster associations and entropy scores. For clarity, subtypes with n > 5 are displayed.CC BY · PubMed Central
Fig. 6 Actionability of mutations by subtype and gene. For each of the 22 most common subtypes: A Frequency of actionable alterations by level of evidence. B Actionable alterations in individual genes, grouped by pathway. Numbers in each cell represent the percentage of samples with actionable alterations in that gene. C Number of actionable alterations per sample. D Frequency of actionable alterations classified by alteration type.
Fig. 6 Actionability of mutations by subtype and gene. For each of the 22 most common subtypes: A Frequency of actionable alterations by level of evidence. B Actionable alterations in individual genes, grouped by pathway. Numbers in each cell represent the percentage of samples with actionable alterations in that gene. C Number of actionable alterations per sample. D Frequency of actionable alterations classified by alteration type.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 236

Metadata

Authors
Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., Zehir, A., Gounder, M. M., Bowler, T. G., Luthra, A., Jadeja, B., Okada, A., Strong, J. A., Stoller, J., Chan, J. E., Chi, P., D’Angelo, S. P., Dickson, M. A., Kelly, C. M., Keohan, M. L., Movva, S., Thornton, K., Meyers, P. A., Wexler, L. H., Slotkin, E. K., Glade Bender, J. L., Shukla, N. N., Hensley, M. L., Healey, J. H., La Quaglia, M. P., Alektiar, K. M., Crago, A. M., Yoon, S. S., Untch, B. R., Chiang, S., Agaram, N. P., Hameed, M. R., Berger, M. F., Solit, D. B., Schultz, N., Ladanyi, M., Singer, S., & Tap, W. D.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
  • Singer, Samuel
  • Tap, William D.
Venue
Nature Communications
Published
2022-06-15
Volume
13
Issue
1
Pages
3405-3405
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4282977145
Cited by
232
References
68
Citations by year
2026: 58 · 2025: 64 · 2024: 59 · 2023: 45 · 2022: 6
FWCI
28.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
U.S. Department of Health & Human Services | National Institutes of Health (P50 CA217694, P30 CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
soft tissue sarcoma, bone sarcoma, sarcoma subtypes, somatic alterations, therapeutic target, whole-genome duplication, mutational signatures, tumor mutational burden, TP53, receptor tyrosine kinase, epigenetic regulators, TERT amplification, intimal sarcoma, uterine adenosarcoma, genomic heterogeneity
MeSH terms
Bone Neoplasms, Humans, Sarcoma, Osteosarcoma, Soft Tissue Neoplasms, Genomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. https://app.cochat.ai/papers/10.1038/s41467-022-30453-x
The paper
Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., Zehir, A., Gounder, M. M., Bowler, T. G., Luthra, A., Jadeja, B., Okada, A., Strong, J. A., Stoller, J., Chan, J. E., . . . Tap, W. D. (2022). Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications. https://doi.org/10.1038/s41467-022-30453-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.